iSpecimen Inc. (NASDAQ:ISPC – Get Free Report) was the target of a large growth in short interest in February. As of February 28th, there was short interest totalling 119,100 shares, a growth of 302.4% from the February 13th total of 29,600 shares. Currently, 14.5% of the shares of the stock are short sold. Based on an average trading volume of 890,700 shares, the days-to-cover ratio is currently 0.1 days.
Institutional Investors Weigh In On iSpecimen
An institutional investor recently bought a new position in iSpecimen stock. Bridgeway Capital Management LLC acquired a new stake in shares of iSpecimen Inc. (NASDAQ:ISPC – Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 21,800 shares of the company’s stock, valued at approximately $58,000. Bridgeway Capital Management LLC owned about 2.27% of iSpecimen as of its most recent SEC filing. 13.62% of the stock is owned by institutional investors and hedge funds.
iSpecimen Stock Performance
Shares of NASDAQ ISPC opened at $1.30 on Thursday. The company’s 50-day moving average price is $2.08 and its 200 day moving average price is $3.08. iSpecimen has a 52 week low of $1.24 and a 52 week high of $11.80. The stock has a market cap of $1.25 million, a price-to-earnings ratio of -0.07 and a beta of 1.65.
About iSpecimen
iSpecimen Inc provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers.
See Also
- Five stocks we like better than iSpecimen
- What Are Treasury Bonds?
- Dividends Are Rising: 3 Foreign Stocks Boosting Payouts
- Russell 2000 Index, How Investors Use it For Profitable Trading
- American Express: A Deep Discount Investors Shouldn’t Ignore
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Nu Holdings: Is Brazil’s Fintech Leader a Buy at This Discount?
Receive News & Ratings for iSpecimen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iSpecimen and related companies with MarketBeat.com's FREE daily email newsletter.